Nuformix (LSE:NFX) Gross-Profit-to-Asset % : 0.00% (As of Sep. 2022)

View and export this data going back to 2015. Start your Free Trial

What is Nuformix Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Nuformix's annualized Gross Profit for the quarter that ended in Sep. 2022 was £0.00 Mil. Nuformix's average Total Assets over the quarter that ended in Sep. 2022 was £4.88 Mil. Therefore, Nuformix's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2022 was 0.00%.

Nuformix Gross-Profit-to-Asset % Historical Data

The historical data trend for Nuformix's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuformix Gross-Profit-to-Asset % Chart

Nuformix Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

-7.49

1.49

4.12

2.39

0.87

Nuformix Semi-Annual Data
	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial									2.00	1.68	-	-	-

Competitive Comparison of Nuformix's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Nuformix's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nuformix's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuformix's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Nuformix's Gross-Profit-to-Asset % falls into.

Nuformix Gross-Profit-to-Asset % Calculation

Nuformix's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Mar. 2022 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Mar. 2022 )	/	( (Total Assets (A: Mar. 2021 )	+	Total Assets (A: Mar. 2022 ))	/ count )
	=	0.048	/	( (6.011	+	4.976)	/ 2 )
	=	0.048	/	5.4935
	=	0.87 %

Nuformix's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2022 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Sep. 2022 )	/	( (Total Assets (Q: Mar. 2022 )	+	Total Assets (Q: Sep. 2022 ))	/ count )
	=	0	/	( (4.976	+	4.78)	/ 2 )
	=	0	/	4.878
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Sep. 2022) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Nuformix Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Nuformix's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuformix (LSE:NFX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuformix PLC (LSE:NFX) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

1RT:Germany

Address

60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR

Website

https://www.nuformix.com

Nuformix PLC is a pharmaceutical development company. It operates in the field of pharmaceutical development targeting unmet medical needs in fibrosis and oncology via drug repurposing. Its pipeline products include NXP001, NXP002, and NXP004. Geographically, the company operates only in the UK.